We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novelion Therapeutics Inc | NASDAQ:NVLN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.68 | 0.63 | 0.6677 | 0 | 01:00:00 |
|
||||
|
|
|
|
|
British Columbia, Canada
|
|
000-17082
|
|
N/A
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
•
|
Financial
: Goals related to the financial performance of the Company on a consolidated basis, which represent 35% of the 2017 corporate goals; these include goals related to the Company’s consolidated 2017 revenues, expenses and cash, as well as certain efforts to realize synergies following the Company’s recent merger transaction.
|
•
|
Drug Development Pipeline
: Goals related to the advancement of the Company’s drug development pipeline, which represent 40% of the 2017 corporate goals; these include goals related to the achievement of certain regulatory events, the development of strategies for certain of the Company’s or its subsidiaries’ drug products and business development goals.
|
•
|
Organizational Transformation
: Goals related to organization development and transformation, which represent 10% of the 2017 corporate goals; these include goals related to public and investor relations, retention of key employees and efforts to identify and implement cost reduction and operational efficiency strategies.
|
•
|
Resolution of Critical Matters and Ongoing Compliance Activities
: Goals related to the final resolution of key litigation and investigations involving the Company’s subsidiary and the implementation of compliance-related agreements and requirements related thereto, which together represent 15% of the 2017 corporate goals.
|
|
||
|
|
|
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release, dated March 15, 2017.
|
99.2
|
|
Risk Factors and Legal Proceedings.
|
|
||
|
|
|
|
Novelion Therapeutics Inc.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Benjamin Harshbarger
|
|
Name:
|
Benjamin Harshbarger
|
|
Title:
|
General Counsel
|
|
||
|
|
|
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release, dated March 15, 2017.
|
99.2
|
|
Risk Factors and Legal Proceedings.
|
1 Year Novelion Therapeutics Chart |
1 Month Novelion Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions